12 Facts About Sun Pharma

Sun Pharma was listed on the stock exchange in 1994 in an issue oversubscribed 55 times.

Sun Pharma has complemented growth with select acquisitions over the last two decades.

In 1996, Sun purchased a bulk drug manufacturing plant at Ahmednagar from Knoll Pharmaceuticals and MJ Pharma's dosage plant at Halol that are both U S FDA approved today.

In 1997, Sun Pharma acquired Tamil Nadu Dadha Pharmaceuticals Limited based in Chennai, mainly for their extensive gynaecology and oncology brands.

Also in 1997, Sun Pharma initiated their first foray into the lucrative US market with the acquisition of Caraco Pharmaceuticals, based in Detroit.

Related searches

In 1998, Sun acquired a number of respiratory brands from Natco Pharma.

In 2011, Sun Pharma entered into a joint venture with MSD to bring complex or differentiated generics to emerging markets .

On 6 April 2014, Sun Pharma acquired Ranbaxy in a US$4 billion landmark transaction to create the world's 5th largest specialty generic pharmaceutical company.

In March 2015, Sun Pharma announced it had agreed to buy GlaxoSmithKline's opiates business in Australia to strengthen its pain management portfolio.

In 2019, Sun Pharma acquired Pola Pharma in Japan to strengthen its global dermatology presence.

Sun Pharma entered the Greater China market by partnering with China Medical System Holdings as well as launched a speciality product, Cequa, in the United States for the treatment of dry eyes.

Sun Pharma stood second in the India's Most Reputed Brands list in a study conducted by BlueBytes, a leading Media Analytics firm in association with TRA Research, a brand insights organization .